Xuerong Biotechnology(SZ:300511) Zheng Quan Zhi Xing·2025-05-13 10:56Core Viewpoint - The company has decided not to exercise the early redemption rights for its convertible bonds, "Xue Rong Convertible Bonds," despite triggering the conditional redemption clause due to stock price performance [1][2][8]. Group 1: Convertible Bond Basic Information - The company issued 5,850,000 convertible bonds on June 24, 2020, with a total fundraising amount of RMB 585 million [2][3]. - The bonds were listed on the Shenzhen Stock Exchange on July 24, 2020, under the code "123056" [3]. - The conversion period for the bonds is from January 4, 2021, to June 23, 2026 [3]. Group 2: Conditional Redemption Clause - The conditional redemption clause allows the company to redeem the bonds if the stock price remains above 120% of the conversion price for at least 15 out of 30 consecutive trading days [7][8]. - The current conversion price is set at RMB 4.10 per share, with the stock price needing to exceed RMB 4.92 to trigger the redemption [1][7]. Group 3: Decision on Redemption - The board of directors has resolved not to exercise the early redemption rights for the next three months, from May 14, 2025, to August 13, 2025 [2][8]. - If the redemption conditions are met again after August 13, 2025, the board will reassess the situation and make a decision accordingly [2][8]. Group 4: Shareholder Transactions - The actual controller, major shareholders, and senior management have not traded the convertible bonds in the six months prior to the redemption conditions being met and have no plans to reduce their holdings in the next six months [8][9]. Group 5: Sponsor's Review Opinion - The sponsor has confirmed that the decision not to redeem the bonds has been approved by the board and complies with relevant regulations and the terms outlined in the offering document [9].